Korro Bio, Inc. (KRRO) Research

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Market snapshot

Symbol
KRRO
Price
$12.99
Day change
+17.56%
Market cap
$129.3M
P/E ratio
-1.33x
52-week range
5.204-55.89
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$19.57

Peer companies

  • Altimmune, Inc. (ALT)
  • Amarin Corporation plc (AMRN)
  • Annexon, Inc. (ANNX)
  • Alto Neuroscience, Inc. (ANRO)
  • Aura Biosciences, Inc. (AURA)
  • DBV Technologies S.A. (DBVT)
  • enGene Holdings Inc. (ENGN)
  • LB Pharmaceuticals Inc Common Stock (LBRX)

Recent insider activity

  • Chappell Todd — S-Sale (3168 shares) on 2026-06-16
  • Vincent Loic A — S-Sale (3418 shares) on 2026-06-16
  • Cerio Jeffrey — S-Sale (6609 shares) on 2026-06-16
  • Dolan Oliver — S-Sale (3383 shares) on 2026-06-16
  • Behbahani Ali — A-Award (14677 shares) on 2026-06-10

Open Korro Bio, Inc. (KRRO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.